Taxol given weekly in advanced previously treated ovarian carcinomas - A pilot study

International Journal of Gynecological Cancer

Volumn 7, Issue 4, 1997, Pages 262-266

  Andersson, H ^a   Horvath, G ^a   Mellqvist, L ^a   Westberg, R ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Chemotherapy; Ovarian cancer; Taxol; Weekly

Indexed keywords

CA 125 ANTIGEN; CIMETIDINE; CLEMASTINE; PACLITAXEL; PLATINUM; PREDNISONE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DOSE RESPONSE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEUROTOXICITY; ONYCHOLYSIS; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0030664470     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.1997.00449.x     Document Type: Article

References (27)

1. McGuire WP, Rowinsky EK, Rosenhein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RS. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
2. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrrett RJ. Phase II trial of pacitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group Study. J Clin Oncol 1994; 12: 1748-53.
3. Seewaldt VL, Greer BE, Cain JM, Figge DC, Tamimi HK, Brown WS, Miller SA. Pacitaxel (Taxol) treatment for refractory ovarian cancer: Phase II clinical trial. Am J Obstet Gynecol 1994; 170: 1666-71.
4. Fenelly D, Shapiro F, Spriggs D, et al. Efficacy and feasibility of weekly taxol administration in patients with taxol refractory ovarian cancer: A phase I study. Proc Am Soc Clin Oncol 1995; 14: 61.
5. Akerley W, Choy H, Rege V, et al. A phase I trial of weekly pacitaxel administrated as a 3 hours indusion for metastatis non-small lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995; 14: 94.
6. Francis P, Rowinsky E, Schneider J, Hoskin W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal pacitaxel: a Gynecologic Oncology Group Pilot Study. J Clin Oncol 1995; 13: 2961-7.
7. Choy H, Safran H. Preliminary analysis of a phase II study of weekly pacitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1995; 22: 4 (Suppl. 9): 55-7.
8. Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ. Weekly, outpatient pacitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol 1995; 22: 5 (Suppl 12): 26-32.
9. Kohn EC, Sarosy G, Bicher A, et al. Dose-intense Taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994; 86: 18-24.
10. Gore ME, Levy V, Rustin G, Perren T, Calvert AH, Earl H, Thompson JM. Pacitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Br J Cancer 1995; 72: 1016-19.
11. Eisenhauer EA, ten Bokkel Huinik WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
12. Cavaletti G, Boglium G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 1995; 75: 1141-50.
13. Postma TJ, Vermerken JB, Liefting AJM, Pinedo HM, Heimans JJ. Pacitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94
14. Francis P, Schneider J, Hann L, Balmaceda C, Barakat R, Philips M, Hakes T. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994;12:2301-8.
15. Padzur R, Lassere Y, Soh LT, et al. Phase II trial of docetaxel (Taxoter®) in metastatic colorectal carcinoma. Ann Oncol 1994; 5: 468-70.
16. Aamdal S, Wolff I, Kaplan S, et al. Docetael (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trial group. Eur J Cancer 1994; 30: 1061-4 (abstr).
17. Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 1995; 21: 463-78.
18. ten Bokkel Huinik WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 527-32.
19. van Hoesel QGCM, Verweij J, Catimel G, et al. For the EORTC Soft Tissue and Bone Sarcoma Group. Phase II study with docetaxel (Taxotere®) in advanced soft tissue sarcomas of the adult. Ann Oncol 1994; 5: 539-42.
20. Curran CF. Onycholysis in doxorubicin-treated patients (letter to the editor). Arch Dermatol 1990; 126: 1244.
21. Cunningham D, Gilchrist NL, Forrest GJ, Soukoop M. Onycholysis associated with cytotoxic drugs. Br J Med 1985; 290: 675-6.
22. Mitchell PLR, Harvey VJ. Mitozantrone-induced Onycholysis. Eur J Cancer 1992; 28: 243-4.
23. Speechely-Dick ME, Owen ERTC. Mitozantrone-induced Onycholysis (letter to the editor). Lancet 1988; 2: 113.
24. Trimble EL, Adams JD, Vena D, et al. Pacitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1993; 11: 2405-10.
25. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992; 10: 1748-53.
26. Philips KA, Friedlander M, Olver I, et al. Australasian multicenter phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Aust NZJ Med 1995; 25: 337-43.
27. Hoekman K, Huijskes RV, Burger CW, Verheijen RH, Pinedo HM, Vermorken JB. Gunstig effect van paclitaxel (Taxol) bij patienten met een met platina vorbehandeld ovariumcarcinoom. Ned Tijdschr Geneeskd 1995; 139: 272-8.